Knight Therapeutics Inc.
KHTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $371,304 | $328,199 | $293,563 | $243,478 |
| % Growth | 13.1% | 11.8% | 20.6% | – |
| Cost of Goods Sold | $196,899 | $175,547 | $155,502 | $128,066 |
| Gross Profit | $174,405 | $152,652 | $138,061 | $115,412 |
| % Margin | 47% | 46.5% | 47% | 47.4% |
| R&D Expenses | $23,304 | $17,549 | $14,755 | $12,692 |
| G&A Expenses | $45,488 | $37,414 | $40,150 | $37,159 |
| SG&A Expenses | $99,349 | $83,693 | $88,624 | $74,376 |
| Sales & Mktg Exp. | $53,861 | $46,279 | $48,474 | $37,217 |
| Other Operating Expenses | $44,355 | $54,300 | $51,742 | $41,176 |
| Operating Expenses | $167,008 | $155,542 | $155,121 | $128,244 |
| Operating Income | $7,397 | -$2,890 | -$2,403 | -$5,322 |
| % Margin | 2% | -0.9% | -0.8% | -2.2% |
| Other Income/Exp. Net | -$5,345 | -$19,098 | -$2,916 | $19,522 |
| Pre-Tax Income | $2,052 | -$21,988 | -$43,960 | $6,690 |
| Tax Expense | -$2,280 | -$5,153 | -$14,068 | -$8,985 |
| Net Income | $4,332 | -$16,835 | -$29,892 | $15,675 |
| % Margin | 1.2% | -5.1% | -10.2% | 6.4% |
| EPS | 0.045 | -0.16 | -0.26 | 0.13 |
| % Growth | 127.9% | 38.5% | -300% | – |
| EPS Diluted | 0.043 | -0.16 | -0.26 | 0.13 |
| Weighted Avg Shares Out | 97,105 | 107,466 | 114,890 | 124,480 |
| Weighted Avg Shares Out Dil | 101,330 | 107,466 | 114,890 | 124,522 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,410 | $12,575 | $10,632 | $7,382 |
| Interest Expense | $9,223 | $12,488 | $6,600 | $3,618 |
| Depreciation & Amortization | $53,109 | $50,397 | $62,621 | $47,915 |
| EBITDA | $64,384 | $40,897 | $25,261 | $42,593 |
| % Margin | 17.3% | 12.5% | 8.6% | 17.5% |